Scientists track hidden heart risks in lifesaving cancer pills
NCT ID NCT07174141
Summary
This study aims to better understand the heart and blood pressure risks linked to newer targeted cancer pills (acalabrutinib, zanubrutinib). Researchers will closely monitor 100 patients taking these drugs for one year to see how often these side effects occur and identify which patients are most at risk. The goal is to help doctors provide safer, more personalized care for people being treated for certain blood cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT WITH SECOND-GENERATION BRUTON'S TYROSINE KINASE INHIBITORS (ACALABRUTINIB, ZANUBRUTINIB) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Dijon Bourgogne
RECRUITINGDijon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.